Update
Retatrutide: what the phase 3 programme does and does not settle
The largest reported weight reduction in the incretin class, from trials that are still running. What that means for a compound already being sold everywhere.
Retatrutide is a triple agonist, acting at the GLP-1, GIP and glucagon receptors, and the phase 2 results reported the largest mean weight reduction of any compound in the class. That figure is why it is already sold widely as a research chemical, years ahead of any approval.
What phase 2 established is an effect size at a range of doses over a defined period — in a selected population — under supervision. What it does not establish is the safety profile over years, the outcome in people excluded from the trial, or what happens on stopping. The glucagon arm is the part with the least precedent behind it, because no approved incretin drug acts there.
The phase 3 programme is where those questions get answered, and it has not finished. Anyone taking retatrutide now is taking a compound whose confirmatory trials are in progress, which is a different proposition from taking one whose trials concluded.
There is a second gap that gets less attention. The trials tested a manufactured product at a known concentration. Material sold as a research chemical is not that product — has no pharmacopoeial standard — and its actual content is whatever a certificate of analysis says it is. That is a claim about one batch, from a lab the seller chose and paid.
Our profile carries the dose ranges the trials used, labelled as trial protocols rather than as recommendations, and the evidence level says early human rather than approved. Both of those will change when the programme reports, and this page will say so when they do.
Compounds this concerns
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.